Citi raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $69 from $65 and keeps a Buy rating on the shares following the FDA approval of Dawnzera. The firm says that while the monthly dose price of $57,462 is higher than Takhzyro and Orladeyo, Dawnzera has a lower annual price given its every-other-month dosing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals price target raised to $82 from $77 at Wells Fargo
- Ionis Pharmaceuticals price target raised to $58 from $57 at Barclays
- Ionis Pharmaceuticals price target raised to $64 from $63 at BofA
- Ionis Pharmaceuticals’ Dawnzera: A Promising New Entrant in HAE Treatment with Strong Market Potential
- Ionis Pharmaceuticals: Strategic Positioning and Revenue Potential Boost Buy Rating